Expert recommendations on the utilization of sodium-glucose cotransporter 2 inhibitors for patients with type 2 diabetes in primary medical institutions

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are increasingly utilized in the treatment of type 2 diabetes, especially for their efficacy in weight reduction and improvement of cardiovascular and renal outcomes, and are progressively gaining widespread utilization in primary medical and healthcare institutions. During their administration, it is imperative to remain vigilant regarding the potential risks of genitourinary infections, SGLT-2i-related ketoacidosis, hypotension, and acute kidney injury in certain patients. This recommendation systematically and popularly introduces the SGLT-2i concept, classification, hypoglycemic mechanism, indications, contraindications, methods of use, super-label scheme, precautions for combined use of SGLT-2i, adverse reactions and their management, as well as the use of SGLT-2i in special patients, in order to help the doctors in primary medical and healthcare institutions to standardize, reasonably and safely use SGLT-2i and correctly grasp the relevant precautions.

Keywords

• primary medical and healthcare institutions，type 2 diabetes mellitus，sodium-glucose cotransporter 2 inhibitors， standardized use of medication